ReviewCurrent opinion in virology2011
Anti-HCV drugs in the pipeline.
Review in Current opinion in virology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 65 citations in OpenAlex.
- In silico prediction of SARS-CoV-2 main protease and polymerase inhibitors: 3D-Pharmacophore modelling.Journal of biomolecular structure & dynamics · 2022Article
- Molecular dynamics simulations and MM-GBSA reveal novel guanosine derivatives against SARS-CoV-2 RNA dependent RNA polymerase.RSC advances · 2022Article
- Deciphering inhibitory mechanism of coronavirus replication through host miRNAs-RNA-dependent RNA polymerase interactome.Frontiers in genetics · 2022Article
- A systematic review of RdRp of SARS-CoV-2 through artificial intelligence and machine learning utilizing structure-based drug design strategy.Turkish journal of chemistry · 2022Review
- Article
- In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses.Viruses · 2020Article
- Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach.Journal of translational medicine · 2020Article
- Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.Life sciences · 2020Article
- Ebola virus glycoprotein GP1-host cell-surface HSPA5 binding site prediction.Cell stress & chaperones · 2020Article
- Potential Drugs and Remedies for the Treatment of COVID-19: a Critical Review.Biological procedures online · 2020Review
- Repurposing therapeutics for COVID-19: Rapid prediction of commercially available drugs through machine learning and docking.PloS one · 2020Article
- Novel inhibitors against wild-type and mutated HCV NS3 serine protease: an in silico study.Virusdisease · 2019Article
- Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses.Journal of medical virology · 2017Article
- IDX-184 is a superior HCV direct-acting antiviral drug: a QSAR study.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2016Article
- Current trends in the treatment of hepatitis C: interventions to avoid adverse effects and increase effectiveness of anti-HCV drugs.EXCLI journal · 2016Review
- Identification of novel anti-hepatitis C virus agents by a quantitative high throughput screen in a cell-based infection assay.Antiviral research · 2015Article
- In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.Antimicrobial agents and chemotherapy · 2014Article
- An interferon-beta promoter reporter assay for high throughput identification of compounds against multiple RNA viruses.Antiviral research · 2014Article
- Hepatitis C virus NS5A inhibitors and drug resistance mutations.World journal of gastroenterology · 2014Review
- Approaches to hepatitis C treatment and cure using NS5A inhibitors.Infection and drug resistance · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Several directly acting and host targeting antivirals that inhibit hepatitis C virus replication have entered clinical trials. Among the most advanced of these are RG7128, an inhibitor of the NS5B polymerase; BMS-790052, an inhibitor of NS5A; and alisporivir, an inhibitor of human cyclophilins. These agents have potent antiviral activity in chronic HCV patients, act additively or synergistically with inhibitors of the HCV NS3/4A protease, and improve the rate of virologic response produced by traditional pegylated interferon plus ribavirin therapy. No cross resistance has been observed; moreover, nucleoside NS5B and cyclophilin inhibitors appear to suppress resistance to non-nucleoside NS5B and NS3/4A inhibitors. Several recent reports of virologic responses produced by combinations of agents that inhibit HCV replication in the absence of interferon provide optimism that eradication of HCV will be possible without interferon in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.